Skip to main content

Advertisement

SpringerLink
Log in

Lupus Nephritis: Review of the Literature

  • Hot Topic
  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Physicians in practice should be knowledgeable regarding several aspects of autoimmune disorders, especially systemic lupus erythematosus (SLE) and lupus nephritis. These disorders can present to the clinician’s clinic and private office regardless of their speciality. This review will discuss various aspects of SLE, its mechanisms of disease, role of accelerated atherosclerosis, proinflammatory cytokines, and therapeutic approaches. The role of vascular endothelial growth factor in which and plasma levels have been associated with disease activity, classification of severity, and diagnosis of lupus nephritis is addressed. Current treatment options, prognosis, and future therapeutic approaches and common side effects are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Smyth A, Oliveira GH, Lahr B, et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol. 2010;5(11):2060–8.

    Article  PubMed  Google Scholar 

  2. de Zubiria Salgado A, Herrera-Diaz C. Lupus nephritis: an overview of recent findings. Autoimmun Dis. 2012;2012:849684.

    Google Scholar 

  3. Bastian HM, Roseman JM, McGwin G Jr, et al. Systemic lupus erythematosus in three ethic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus. 2002;11(3):152–60.

    Google Scholar 

  4. •• Frieri M. Mechanisms of disease for the clinician: systemic lupus erythematosus. Ann Allergy Asthma Immunol. 2013;110:228–32. This article lists the mechanisms of SLE for the clinician, documenting complex interactions and listing important literature in peer-reviewed journals on the clinical and immunologic features, pathogenesis, epidemiology, laboratory evaluation, and treatment of SLE.

    Article  PubMed  Google Scholar 

  5. •• Frieri M. Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. Curr Allergy Asthma Rep. 2012;12(1):25–32. This paper discusses disturbances in gene expression involved in lipid transport and atheroma promotion and provides evidence of the immune system in accelerated atherosclerosis in SLE, the role of selected proinflammatory cytokines, and therapeutic approaches.

    Article  PubMed  CAS  Google Scholar 

  6. Kaplan J, Anand P, Frieri M. Rash, drug hypersensitivity and autoimmunity in a 20 year old. Ann Allergy Asthma Immunol. 2005;95:111–4.

    Article  PubMed  Google Scholar 

  7. Horne NS, Narayan AR, Young RM, Frieri M. Toxic epidermal necrolysis in systemic lupus erythematosus. Autoimmun Rev. 2006;5:160–4.

    Article  PubMed  Google Scholar 

  8. Frieri M. Identification of masqueraders of autoimmune disease in the office. Allergy Asthma Proc. 2003;24(6):421–9.

    PubMed  Google Scholar 

  9. •• Zubair A, Frieri M. NF-κB and systemic lupus erythematosus:examining the link .JNephrolD-13-00003R1, online on 6/14/2013. This paper reviews the link between NF-κB and SLE, including B-cell development, signaling, and cytokines which play a crucial role in the pathogenesis of SLE and T-cell development and activation. The roles of dendritic cells polymorphisms, NF-κB, which are linked with SLE and Toll-like receptors, are also discussed.

  10. Gordon C, Jayne D, Pusey C, et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus. 2009;18(3):257–63.

    Article  PubMed  CAS  Google Scholar 

  11. Cameron JS. Lupus nephritis. J Am Soc Nephrol. 1999;10(2):413–24. activity.

    PubMed  CAS  Google Scholar 

  12. Weening JJ, D’Agati VD, Schwartz M, et al. The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. J Am Soc Nephrol. 2004;15(2):241–50.

    Article  PubMed  Google Scholar 

  13. Avihingsanon Y, Hirankarn N. Major lupus organ involvement: severe lupus nephritis. Lupus. 2010;19(12):1391–8.

    Article  PubMed  CAS  Google Scholar 

  14. Navarro C, Candia-Zúñiga L, Silveira LH, et al. Vascular endothelial growth factor plasma levels in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Lupus. 2002;11(1):21–4.

    Article  PubMed  CAS  Google Scholar 

  15. Feliers D. Vascular endothelial growth factor as a prognostic marker of lupus nephritis. Kidney Int. 2009;75(12):1251–3.

    Article  PubMed  CAS  Google Scholar 

  16. Zhu L, Shi S, Liu LT, et al. Increased plasma sVCAM-1 is associated with severity in IgA nephropathy. BMC Nephrol. 2013;14:21.

    Article  PubMed  CAS  Google Scholar 

  17. Yedowitz JC, Frieri M. Cytokine and growth factor production from chlamydia pneumoniae hsp 60 stimulated human aortic endothelial cells in the presence of simvastatin. Ann Allergy Asthma Immunol. 2009;102:P113.

    Google Scholar 

  18. Law ST, Ma KM, Li KK. Clinical characteristics of concurrent and sequentially presented lupus-related protein-losing enteropathy: what are their differences? Rheumatol Int. 2013;33(1):85–92.

    Article  PubMed  CAS  Google Scholar 

  19. Awazawa R, Yamamoto Y, Mine Y, et al. Systemic lupus erythematosus complicated with protein-losing enteropathy: a case report and review of the published works. J Dermatol. 2012;39(5):454–61.

    Article  PubMed  CAS  Google Scholar 

  20. Chang YS, Lai CC, Chen WS, et al. Protein-losing enteropathy and premature ovarian failure in a young woman with systemic lupus erythematosus. Lupus. 2012;21(11):1237–9.

    Article  PubMed  CAS  Google Scholar 

  21. Law ST, Ma KM, Li KK. The clinical characteristics of lupus related protein-losing enteropathy in Hong Kong Chinese population: 10 years of experience from a regional hospital. Lupus. 2012;21(8):840–7.

    Article  PubMed  CAS  Google Scholar 

  22. Akkina SBK, Frieri M. Systemic lupus erythematosus, protein losing enteropathy & autoimmune hemolytic anemia. Ann Allergy Asthma Immunol. 2012;109:77a. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies.

    Article  Google Scholar 

  23. Mosca M, Tani C, Aringer M, et al. League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010;69(7):1269–74.

    Article  PubMed  CAS  Google Scholar 

  24. Hara M, Nemoto T, Hijima T, et al. A case of IgA nephropathy associated with mycosis fungoides that developed into rapidly progressive glomerulonephritis. Clin Nephrol. 2013;79(2):161–5.

    Article  PubMed  Google Scholar 

  25. Wu G, Peng YM, Liu FY et al. The role of memory B cell in tonsil and peripheral blood in the clinical progression of IgA nephropathy. Hum Immunol. 2013;74(6):708–12.

    Google Scholar 

  26. Akkina S, Frieri M. Stable IgA nephropathy post renal transplantation on immune suppressive therapy. Ann Allergy Asthma Immunol. 2012;109:302a.

    Google Scholar 

  27. Lee H, Kim DK, Oh K, et al. Mortality and renal outcome of primary glomerulonephritis in Korea: observation in 1,943 biopsied cases. Am J Nephrol. 2013;37(1):74–83.

    Article  PubMed  CAS  Google Scholar 

  28. •• Frieri M, Samih MA, Dzhindzhikhashvili M, Liu H, et al. Toll-like receptor 9 and vascular endothelial growth factor levels in human kidneys from lupus nephritis patients. J Nephrol. 2012;25(6):1041–6. This is the first study that investigated combined expression of TLR9 and VEGF, which could be an important tool for understanding the role of TLR9 and VEGF in lupus nephritis with insights into the early detection and targeted treatment of this disease.

    Article  PubMed  CAS  Google Scholar 

  29. • Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797–808. This report, developed using validated guidelines methodology, represents the American College of Rheumatology’s recommendations for the case identification, treatment, and monitoring of lupus nephritis.

    Article  Google Scholar 

  30. Lightstone L. Lupus nephritis: where are we now? Curr Opin Rheumatol. 2010;22(3):252–6.

    Article  PubMed  Google Scholar 

  31. Markowitz GS, D’Agati VD. Classification of lupus nephritis. Curr Opin Nephrol Hypertens. 2009;18(3):220–5.

    Article  PubMed  CAS  Google Scholar 

  32. Frieri M, Akkina SA. Case of Persistent Eosinophilia in Lupus Nephritis. P108. Ann Allergy Asthma Immunol. 2011;107:P108.

    Google Scholar 

  33. Giannakakis K, Faraggiana T. Histopathology of lupus nephritis. Clin Rev Allergy Immunol. 2011;40(3):170–80.

    Article  PubMed  Google Scholar 

  34. Sada KE, Makino H. Usefulness of ISN/RPS classification of lupus nephritis. J Korean Med Sci. 2009;Suppl:S7–10.

    Google Scholar 

  35. Marks SD, Tullus K. Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis. Acta Paediatr. 2010;99(7):967–74.

    Article  PubMed  CAS  Google Scholar 

  36. •• Mok C.C. Biomarkers for lupus nephritis: a critical appraisal. J Biomed Biotechnol, 2010;638413. Novel biomarkers are necessary to enhance the diagnostic accuracy and sensitivity of lupus renal disease, prognostic stratification, monitoring of treatment response, and detection of early renal flares. This paper reviews promising biomarkers that have recently been evaluated in longitudinal studies of lupus nephritis.

  37. Canetta PA, Bomback AS, Radhakrishnan J. Treating lupus in the kidney: where are we now, and where are we going? Discov Med. 2011;12(65):341–9.

    PubMed  Google Scholar 

  38. Houssiau F. Toward better treatment for lupus nephritis. N Engl J Med. 2011;365(20):1929–30.

    Article  PubMed  CAS  Google Scholar 

  39. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110–21.

    Article  PubMed  CAS  Google Scholar 

  40. Yee CS, Gordon C. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350(24):2518–20. author reply 2518-2520.

    Article  PubMed  CAS  Google Scholar 

  41. Dolff S, Berden JH, Bijl M. Treatment of lupus nephritis. Expert Rev Clin Immunol. 2010;6(6):901–11.

    Article  PubMed  Google Scholar 

  42. Alshayeb H, Wall BM, Gosmanova EO. Treatment of proliferative and membranous lupus nephritis: review of key clinical trials. Am J Med Sci. 2012;343(1):86–90.

    Article  PubMed  Google Scholar 

  43. Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69(12):2083–9.

    Article  PubMed  CAS  Google Scholar 

  44. Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford). 2010;49(1):128–40.

    Article  Google Scholar 

  45. Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis. 2011;57(2):235–44.

    Article  PubMed  CAS  Google Scholar 

  46. Lee YH, Woo JH, Choi SJ, et al. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lupus. 2010;19(6):703–10.

    Article  PubMed  CAS  Google Scholar 

  47. Houssiau FA, Ginzler EM. Current treatment of lupus nephritis. Lupus. 2008;17(5):426–30.

    Article  PubMed  CAS  Google Scholar 

  48. Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol. 2010;21(12):2028–35.

    Article  PubMed  CAS  Google Scholar 

  49. Zeher M, Doria A, Lan J, et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus. 2011;20(14):1484–93.

    Article  PubMed  CAS  Google Scholar 

  50. El-Shafey EM, Abdou SH, Shareef MM. Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients? Clin Exp Nephrol. 2010;14(3):214–21.

    Article  PubMed  CAS  Google Scholar 

  51. Allen BC, Mohammed TL, Tan CD, et al. Metastatic melanoma to the heart. Curr Probl Diagn Radiol. 2012;41(5):159–64.

    Article  PubMed  Google Scholar 

  52. Navaneethan SD, Viswanathan G, Strippoli GF. Treatment options for proliferative lupus nephritis: an update of clinical trial evidence. Drugs. 2008;68(15):2095–104.

    Article  PubMed  CAS  Google Scholar 

  53. Bargman JM. How did cyclophosphamide become the drug of choice for lupus nephritis? Nephrol Dial Transplant. 2009;24(2):381–4.

    Article  PubMed  Google Scholar 

  54. Touma Z, Gladman DD, Urowitz MB, et al. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol. 2011;38(1):69–78.

    Article  PubMed  CAS  Google Scholar 

  55. Kamanamool N, McEvoy M, Attia J, et al. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis. Medicine (Baltimore). 2010;89(4):227–35.

    Article  CAS  Google Scholar 

  56. Laskari K, Mavragani CP, Tzioufas AG, et al. Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study. Arthritis Res Ther. 2010;12(6):R208.

    Article  PubMed  Google Scholar 

  57. Rabrenovic V, Poskurica M, Kovacevic Z, et al. Treatment of lupus nephritis by mycophenolate mofetil. Kidney Blood Press Res. 2010;33(4):297–303.

    Article  PubMed  CAS  Google Scholar 

  58. • Radhakrishnan J, Moutzouris DA, Ginzler EM, et al. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010;77(2):152–60. This study pools analyses of two large randomized controlled multicenter trials of patients with diverse ethnic and racial background who had pure class V disease. Tthe response to mycophenolate mofetil as induction treatment of patients with class V LN appeared to be no different from that of intravenous cyclophosphamide.

    Article  PubMed  CAS  Google Scholar 

  59. •• Arends S, Grootscholten C, Derksen RH, et al. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. Ann Rheum Dis. 2012;71(6):966–73. Induction treatment with high-dose intravenous cyclophosphamide was superior to azathioprine/methylprednisolone in preventing renal relapses, but other parameters for renal function did not differ. Azathioprine/methylprednisolone can therefore serve as an alternative in patients with proliferative lupus nephritis who wish to avoid the gonadal toxicity of cyclophosphamide Several prognostic factors of long-term renal outcome were identified.

    Article  PubMed  CAS  Google Scholar 

  60. Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365(20):1886–95.

    Article  PubMed  CAS  Google Scholar 

  61. Khajehdehi P, Zanjaninejad B, Aflaki E, et al. Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study. J Ren Nutr. 2012;22(1):50–7.

    Article  PubMed  CAS  Google Scholar 

  62. Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol. 2011;7(12):718–29.

    Article  PubMed  CAS  Google Scholar 

  63. Masood S, Jayne D, Karim Y. Beyond immunosuppression - challenges in the clinical management of lupus nephritis. Lupus. 2009;18(2):106–15.

    Article  PubMed  CAS  Google Scholar 

  64. Mina R, von Scheven E, Ardoin S, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012;64(3):375–83.

    Article  Google Scholar 

  65. Aragon E, Chan YH, Ng KT, et al. Good outcomes with mycophenolate-cyclosporine-based induction protocol in children with severe proliferative lupus nephritis. Lupus. 2010;19(8):965–73.

    Article  PubMed  CAS  Google Scholar 

  66. Weng MY, Weng CT, Liu MF. The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus. Clin Rheumatol. 2010;29(7):771–5.

    Article  PubMed  Google Scholar 

  67. Appel GB. New and future therapies for lupus nephritis. Cleve Clin J Med. 2012;79(2):134–40.

    Article  PubMed  Google Scholar 

  68. Ogawa H, Kameda H, Amano K, et al. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus. 2010;19(2):162–9.

    Article  PubMed  CAS  Google Scholar 

  69. Appel AS, Appel GB. An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases. Nat Clin Pract Nephrol. 2009;5(3):132–42.

    Article  PubMed  CAS  Google Scholar 

  70. Jonsdottir T, Sundelin B, Welin Henriksson E, et al. Rituximab-treated membranous lupus nephritis: clinical outcome and effects on electron dense deposits. Ann Rheum Dis. 2011;70(6):1172–3.

    Article  PubMed  Google Scholar 

  71. Bertsias G, Boumpas DT. Update on the management of lupus nephritis: let the treatment fit the patient. Nat Clin Pract Rheumatol. 2008;4(9):464–72.

    Article  PubMed  Google Scholar 

  72. Tesar V, Hruskova Z. Treatment of proliferative lupus nephritis: a slowly changing landscape. Nat Rev Nephrol. 2011;7(2):96–109.

    Article  PubMed  CAS  Google Scholar 

  73. Berthier CC, Kretzler M, Davidson A. From the large scale expression analysis of lupus nephritis to targeted molecular medicine. J Data Min Genomics Proteomics 2012;3(3):1000123.

    Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Adeel Zubair and Marianne Frieri declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Mayo Medical School, 200 1st St SW, Rochester, MN, 55905, USA

    Adeel Zubair

  2. Department of Medicine and Pediatrics, Nassau University, Medical Center, 2201 Hempstead Turnpike, East Meadow, NY, 11554, USA

    Marianne Frieri

Authors
  1. Adeel Zubair
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marianne Frieri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marianne Frieri.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zubair, A., Frieri, M. Lupus Nephritis: Review of the Literature. Curr Allergy Asthma Rep 13, 580–586 (2013). https://doi.org/10.1007/s11882-013-0394-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11882-013-0394-4

Keywords

Search

Navigation